To discover therapeutic approaches to target HOXB13 loss in metastatic PCa, we tested the clinically available p300/CBP inhibitor CCS1477, since p300 and CBP are required for HOXB13-loss-induced lipogenic gene expression. Here, CREBBP is linked to posterior cortical atrophy.